Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907173 · ClinicalTrials.gov registry record · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
A Phase 3 study of Status Epilepticus, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
- 20
- Study locations
NCT06907173: Recruiting Phase 3 study of Status Epilepticus, sponsored by University of Virginia.
NCT06907173 is a Phase 3 study of Status Epilepticus that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 770 participants, below the 2,756-participant average among 10 other Status Epilepticus trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907173, a Phase 3 study of Status Epilepticus, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
Primary Outcome
Termination of SE from 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication. Termination of SE is determined by (1) improving consciousness and absence of clinically apparent seizures at 60 minutes or (2) absence of any electrographic status epilepticus (ESE) after 15 minutes in those with EEG monitoring and no improvement in consciousness.
Conditions Studied
Interventions
- DRUG Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)
- DRUG Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)
- DRUG Levetiracetam (LEV) (60 mg/Kg)
Study Locations (20)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- Children's Hospital Los Angeles - Los Angeles
- UC Davis Medical Center - Sacramento
Illinois
- Northwestern Memorial Hospital - Chicago
- Comer Children's Hospital - Chicago
- University of Chicago Medical Center - Chicago
Delaware
- Christiana Hospital - Newark
- Nemours Children's Hospital - Wilmington
North Carolina
- Duke Regional Hospital - Durham
- Duke University Hospital - Durham
Alabama
- Arthur M. Blank Hospital - Georgia
Arizona
- Banner University Medical Center - Tucson Campus - Tucson
Connecticut
- Yale New Haven Hospital - New Haven
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2026-02 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
What NCT06907173 shows while recruiting
NCT06907173 is an interventional study that assigns participants to a tested intervention. The registered 770 participants enrollment target is mid-sized for trials with a published cap, below the 2,756-participant average among 10 other Status Epilepticus trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Status Epilepticus appearing as the primary indexed condition, and to 3 interventions - of which Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET) is the first listed.
NCT06907173 names 20 study sites across 14 states, led by California, Illinois, Delaware.
Frequently Asked Questions
What is clinical trial NCT06907173 about?
NCT06907173 is a clinical study titled "Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)". The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
What is the current status of trial NCT06907173?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2026-02. Estimated completion is 2029-12.
What conditions does trial NCT06907173 study?
This clinical trial studies the following conditions: Status Epilepticus.
What interventions are being tested in trial NCT06907173?
The interventions under investigation include: Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET) (DRUG), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET) (DRUG), Levetiracetam (LEV) (60 mg/Kg) (DRUG).
Who is sponsoring clinical trial NCT06907173?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907173 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Status Epilepticus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06907173's enrollment target sits among peer trials
770 4th of 10 higher than 7 of 10 other Status Epilepticus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Status Epilepticus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications
COMPLETED · Phase 3
-
Simulation Trial of Telemedical Support for Paramedics
RECRUITING · NA
-
Improving Status Epilepticus Treatment Times
RECRUITING · NA
-
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
RECRUITING · Phase 2
-
Rapid-Response EEG in Children With Suspected Status Epilepticus
RECRUITING
-
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06376994 · 770 participants · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
- NCT06824467 · 770 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- NCT07209254 · 770 participants · NA
Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia